RESEARCH ARTICLE

Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study

Togo Iwahana*, Yuichi Saito, Sho Okada, Hirotoshi Kato, Ryohei Ono, Yoshio Kobayashi

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

* adxa2698@chiba-u.jp

Abstract

Esaxerenone, a mineralocorticoid receptor blocker (MRB), is a new antihypertensive agent. However, esaxerenone-related data with respect to hypertension with heart failure are limited. We investigated the safety and efficacy of esaxerenone in hypertensive patients with heart failure with reduced ejection fraction (HFrEF). Hypertensive patients with HFrEF treated with esaxerenone were retrospectively analyzed at two timepoints (short-term: 35 ±15 days; mid-term: 167±45 days). Adverse events including hyperkalemia (K+ >5.5 mEq/L), worsening renal function (WRF; estimated glomerular filtration rate (eGFR) reduction by ≥20%), and hypotension (systolic blood pressure <90 mmHg) were evaluated. eGFR and K+, serum creatinine, and brain natriuretic peptide (BNP) levels at baseline, short-term, and mid-term assessments were compared. Patients administered esaxerenone as their first MRB (first-MRB cohort) and those who converted from another MRB (conversion cohort) were separately analyzed. There were 50 (56±10 years old, 26% female) patients. At the short-term assessment, hyperkalemia or hypotension was not observed at a dose of 2.0 ±0.9 mg/day. Seven patients (14%) showed WRF. K+ was slightly elevated (4.12±0.41 to 4.25±0.39 mmol/L, p = 0.07) and eGFR was significantly reduced (66.9±19.6 mL/min/1.73 m² to 62.4±19.7 mL/min/1.73 m², p = 0.006). In the conversion cohort, significant changes in K+ and eGFR from baseline were not observed at the short-term assessment. BNP levels were consistently improved regardless of the cohorts (first-MRB cohort, 310 [110–370] pg/mL to 137 [47–152] pg/mL, p = 0.001; conversion cohort, 181 [30–203] pg/mL to 108 [26–146] pg/mL, p = 0.028). At the mid-term assessment, there were no significant changes in K+ and eGFR compared with the short-term assessment. In conclusion, esaxerenone was safe for hypertensive patients with HFrEF. Hyperkalemia and hypotension were rarely noted, while eGFR was marginally reduced. Moreover, esaxerenone might be beneficial for HFrEF in terms of BNP level reduction.
Introduction

Hypertension is a major risk factor for heart failure (HF) [1]. Mineralocorticoid receptor (MR)-associated hypertension, in which MR is excessively stimulated, is detected in a proportion of patients presenting with resistant hypertension [2]. In patients with MR-associated hypertension, MR blockers (MRBs) with first-line antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics have been suggested to be effective in controlling blood pressure (BP) [3].

MRBs have also improved the prognosis of HF with reduced ejection fraction (HFrEF) in previous studies, such as RALES [4], EPHESUS [5], and EMPHASIS-HF [6]. Administration of MRBs with ACE inhibitors or ARBs, and β-blockers for patients with HFrEF has been recommended according to the guidelines [7,8].

Recently, the FIDELIO-DKD trial investigating the kidney and cardiovascular outcomes and safety of finerenone, a novel non-steroidal MRB, compared with a placebo in patients with type 2 diabetes and chronic kidney disease with albuminuria was published [9]. Patients in the finerenone group showed a significant decrease of kidney disease progression or cardiovascular death compared to the placebo group, suggesting that MRBs improve both the renal and cardiovascular prognosis in patients with diabetic nephropathy [9].

Although MRBs are essential in the treatment of resistant hypertension and HFrEF, they have several problems. Hyperkalemia is one of the most important adverse events (AEs). In addition, spironolactone results in gynecomastia [4], while eplerenone is contraindicated in diabetic patients with microalbuminuria or proteinuria and in those with moderate or severe renal dysfunction (creatinine clearance <50 mL/min) [10]. Furthermore, hypotension is also an issue in the treatment of HF.

Esaxerenone is a novel, non-steroidal, and selective MRB [11]. It was developed in Japan and was approved as an antihypertensive agent [11]. The ESAX-HTN phase 3 trial [12] has reported that treatment with esaxerenone (2.5 and 5 mg/day) in patients with essential hypertension is non-inferior to that with eplerenone (50 mg/day). Moreover, the incidence of AEs, such as hyperkalemia and worsening of renal failure (WRF), was similar between the two.

Esaxerenone is expected to be beneficial in patients with HF; however, it is only indicated for hypertensive patients in Japan. Data on esaxerenone for HF, especially for HFrEF, are limited. In the present study, we investigated the short- to mid-term safety and efficacy of esaxerenone in patients with hypertension with HFrEF.

Materials and methods

Study design

This was a single-center, retrospective observational study conducted in Chiba University Hospital. In order to investigate the safety and efficacy of esaxerenone for hypertensive patients with HFrEF, laboratory and BP data obtained before and after the administration of esaxerenone were retrospectively analyzed. This study protocol was approved by the Ethics Committee of Chiba University in accordance with the 2013 Declaration of Helsinki.

Patient selection

Hypertensive patients with HFrEF who were newly treated with esaxerenone at the Chiba University Hospital between July 2019 and January 2021 were retrospectively included. Hypertension was defined as a systolic BP (SBP) >140 mmHg and/or diastolic BP (DBP) >90 mmHg or those who were already prescribed with antihypertensive agents due to a diagnosis of...
hypothesis. The criteria for HFrEF were as follows: (i) left ventricular ejection fraction (LVEF) <40%, and (ii) New York Heart Association (NYHA) class II, III, or IV. Patients with baseline serum potassium (K⁺) levels >5 mEq/L or those lost to follow-up were excluded. All participants were given the option to opt out of the study through a notice on the website.

Study protocol
Baseline characteristics including age, sex, body mass index (BMI), NYHA class, etiology of HF, BP, heart rate (HR), comorbidities, current antihypertensive agents, laboratory data including serum creatinine (Cre), K⁺, and brain natriuretic peptide (BNP) levels, and echocardiographic data were collected from medical records. The estimated glomerular filtration rate (eGFR) was calculated using the Japanese GFR equation: eGFR = 194 × Cre¹.094 × Age⁻⁰.²⁸⁷ × 0.⁷³⁹ (if female) [13].

Esaxerenone was usually started at a dose of 2.5 mg daily. However, in patients with renal dysfunction (eGFR <60 mL/min/1.73 m²) or low cardiac function, the initial dose was 1.25 mg daily according to their physicians’ discretion. The dose was titrated by monitoring BP and blood examination to a maximum dose of 5 mg daily.

In the short-term assessment, BP and laboratory data obtained at the first evaluation two weeks after the initiation of esaxerenone were compared with baseline data. Mid-term assessment was performed at 6±2 months after the initiation of esaxerenone in patients whose data were available. The primary endpoint was the incidence of AEs, such as hyperkalemia, WRF, hypotension, and cardiovascular events. The secondary endpoint was changes in blood examination findings, such as changes in K⁺, Cre, eGFR, and BNP levels. For patients whose data were available, the changes in BP were also analyzed (Fig 1).

As a sub-analysis, patients who were converted from another MRB to esaxerenone (conversion cohort) and patients who took esaxerenone as their first MRB (first MRB cohort) were separately analyzed (Fig 1).

Definition of AEs
Hyperkalemia was defined as K⁺ >5.5 mEq/L, WRF as ≥20% in eGFR decrease, and hypotension as SBP <90 mmHg at clinic and/or home BP measurement. Cardiovascular event was defined as an all-cause death and hospitalization due to worsening HF.

Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) and were compared using the paired t-test. BNP was expressed as median [IQR] and compared using the Wilcoxon signed-rank test. Categorical variables were expressed as numbers and percentages and were compared using the chi-squared test. Statistical significance was set at p<0.05. Processing and statistical analyses were performed using JMP® Pro.14.2.0 (SAS Institute, Cary, NC).

Results
Baseline characteristics
A total of 93 patients with hypertension and HF with newly introduced esaxerenone were identified. The following patients were excluded: 35 patients with LVEF ≥40%, 5 patients lacking follow-up laboratory data, and 3 patients who discontinued esaxerenone within 2 weeks. Thus, 50 patients were included in this study. The reasons for the three patients’ esaxerenone discontinuation within 2 weeks were K⁺ elevation, eGFR reduction (not reaching the AE
criterion), and planned cardiac surgery, respectively. A total of 30 patients (60%) were converted from another MRB. Baseline characteristics are presented in Table 1.

**Short-term assessment**

In the short-term assessment at 35±15 days after initiation of esaxerenone, the average dose of esaxerenone was 2.0±0.9 mg/day. The number of antihypertensive agents taken by patients significantly increased; however, the usage rates of each antihypertensive agent except for MRBs were similar (Table 2). The dose of β-blockers (carvedilol equivalent dose) was slightly reduced and that of loop diuretics (furosemide equivalent dose) was similar (Table 2).

No patients were deemed hyperkalemic. The mean K⁺ elevation was 0.13±0.50 mEq/L, which was not significant (Fig 2A). WRF was observed in 7 patients (14%), and the mean changes in Cre and eGFR were 0.06±0.17 mg/dL (p = 0.01) and -4.5±10.9 mL/min/1.73 m² (p<0.01), respectively (Fig 2B and 2C). BNP levels significantly decreased from 232 [45–354] pg/mL to 120 [37–149] pg/mL (p<0.01) (Fig 2D). Clinic BP data of 37 patients (74%) were available. Home BP records were also checked to evaluate the presence of hypotension. SBP was slightly decreased with marginal significance (128±22 mmHg to 121±16 mmHg, p = 0.06), whereas DBP was similar (78±15 mmHg to 75±15 mmHg, p = 0.78). None of the patients presented with hypotension.
| Table 1. Baseline patient characteristics. |
|------------------------------------------|
| **Age, years old** | 55.9 ± 15.0 |
| **Male, n (%)** | 37 (74%) |
| **Body weight, kg** | 75.0 ± 19.4 |
| **BMI, kg/m²** | 26.3 ± 6.2 |
| **NYHA 3/4, n (%)** | 14 (28%) |
| **ICM, n (%)** | 7 (14%) |
| **Non-ICM, n (%)** | 43 (86%) |
| **Comorbidities** |
| AF, n (%) | 14 (28%) |
| DM, n (%) | 12 (24%) |
| Dyslipidemia, n (%) | 24 (48%) |
| CKD, n (%) | 15 (30%) |
| **Device Therapies** |
| ICD, n (%) | 4 (8%) |
| CRT/CRT-D, n (%) | 7 (14%) |
| **Antihypertensive Agents** |
| ACE inhibitors/ARBs, n (%) | 43 (86%) |
| CCBs, n (%) | 9 (18%) |
| Diuretics, n (%) | 40 (80%) |
| MRBs, n (%) | 30 (60%) |
| Spironolactone, n (%) | 21 (42%) |
| Eplerenone, n (%) | 9 (18%) |
| β-blockers, n (%) | 44 (88%) |
| α-blockers, n (%) | 1 (2%) |
| **Number of antihypertension agents, n** | 3.4 ± 0.9 |
| **Systolic blood pressure, mmHg** | 128 ± 22 |
| **Diastolic blood pressure, mmHg** | 78 ± 15 |
| **Heart rate, bpm** | 79 ± 15 |
| **Laboratory** |
| Cre, mg/dL | 0.95 ± 0.34 |
| eGFR, mL/min/1.73 m² | 66.9 ± 19.6 |
| K, mEq/L | 4.1 ± 0.4 |
| BNP, pg/mL | 167 [63–375] |
| **Echocardiography** |
| LVEF, % | 31 ± 6 |
| LVDD, mm | 62 ± 8 |
| LVDS, mm | 53 ± 8 |
| IVST, mm | 9 ± 2 |
| LVPW, mm | 10 ± 2 |
| LAVI, mL/m² | 46.5 ± 22.1 |
| E/A | 1.19 ± 1.00 |
| E/e’ | 13.0 ± 7.0 |

Data are presented as the mean ± SD unless specified. BNP was expressed as the median [IQR].

Abbreviations: BMI, body mass index; NYHA, New York Heart Association functional class; AF, atrial fibrillation; DM, diabetes mellitus; CKD, chronic kidney disease; ICD, implantable cardiac defibrillator; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; ACE, angiotensin converting enzyme; ARB angiotensin II receptor blocker; CCB, calcium channel blocker; MRB, mineralocorticoid receptor blocker; Cre, serum creatinine; eGFR, estimated glomerular filtration rate; K, serum potassium; BNP, plasma brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVDD, left ventricular end-diastolic diameter; LVDS, left ventricular end-systolic diameter; IVST, interventricular septal thickness; LVPW, left ventricular posterior wall; LAVI, left atrial volume index.

https://doi.org/10.1371/journal.pone.0259485.t001
In the first-MRB cohort (n = 20) in the short-term assessment, the changes in K^+, Cre, and eGFR were significant (Fig 3A–3C). Six patients (30%) presented with WRF; however, none had hyperkalemia. Analysis of BP in the first-MRB cohort (n = 16) showed a significant decrease in SBP (138 ± 24 mmHg to 127 ± 18 mmHg, p = 0.03).

The short-term assessment in the conversion cohort (n = 30) showed that there was no significant change in K^+, Cre, or eGFR compared with their baseline values (Fig 3A–3C). In both cohorts, BNP levels were consistently lowered (Fig 3D).

### Mid-term assessment

The mid-term assessment was performed in 38 patients with data obtained at 167±45 days after initiation of esaxerenone. Esaxerenone was titrated to 2.8±1.3 mg/day (p<0.01), and the number of antihypertensive agents was similar to that in the short-term assessment (4.0±0.6, p = 0.71). Six patients (16%) presented with WRF, and none had hyperkalemia. Neither K^+, Cre, nor eGFR changed compared to the short-term assessment (Fig 4A–4C). BNP was consistently lowered compared to that in the short-term assessment (Fig 4D).

### Discussion

In the present study, we investigated the safety and efficacy of esaxerenone in hypertensive patients with HFrEF. The main findings were as follows: (i) K^+ level was slightly elevated with mild eGFR reduction; (ii) significant changes in K^+ levels and renal function were not observed in patients converted from another MRB; and (iii) BNP was consistently decreased regardless of previous MRB treatment.
There are limited data on the usage of esaxerenone in the treatment of HF. Naruke et al. firstly reported detailed changes in BP and treatment-related AEs in hypertensive patients with HF [14]. This retrospective study included patients regardless of LVEF, where the majority (82%) of patients had LVEF \( \leq 40\% \). Since MRBs other than esaxerenone have been shown to be effective for HFrEF, analyses of esaxerenone focused on HFrEF are required. However, there are concerns of MRB-induced hypotension and peripheral circulatory failure, especially in patients with HFrEF. Therefore, we mainly investigated the safety of esaxerenone as well as efficacy focused in hypertensive patients with HFrEF. To our knowledge, this is the first report regarding the safety and efficacy of esaxerenone in HFrEF patients. Moreover, our study included a number of patients who were converted from another MRB.

**Safety for K^+ levels and renal function**

Hyperkalemia is one of the most important AEs of MRB [15]. EMPHASIS-HF [6], a study investigating the efficacy and safety of eplerenone for symptomatic HFrEF patients, showed
that the mean change in K+ level after a month was 0.16±0.51 mEq/L. Hyperkalemia (K+>5.5 mEq/L) occurred in 11.8% [6]. Several phase III clinical trials of esaxerenone, which included patients with essential hypertension, hypertension with renal dysfunction, type 2 diabetes, or primary aldosteronism, but all without HF, showed that hyperkalemia occurred in 1.7% of esaxerenone-treated patients (including unpublished data) [12,16–18]. In the present study, no patient showed hyperkalemia, although K+ was similarly elevated by 0.28±0.59 mEq/L in the first-MRB cohort in the short-term assessment. It has been reported that MRB treatment causes a temporary eGFR decrease by relieving glomerular hyperfiltration [19]. However, MRBs had significant antiproteinuric and antialbuminuric effects and improved cardiorenal prognosis when added to ACEIs or ARBs [20]. In the present study, patients in the first-MRB cohort showed an increase in Cre by 0.12±0.22 mg/dL, which was comparable with the results of the EMPHASIS-HF trial (0.15±0.35 mg/dL) [6]. It should be noted that 30% of patients presented with WRF in the first-MRB cohort. In fact, five of the six patients presenting with WRF started on 2.5 mg of esaxerenone. To avoid a sharp change in renal function, initiation from 1.25 mg seems to be safer.
In the conversion cohort, K\textsuperscript{+}, Cre, and eGFR did not significantly change, suggesting that the risks of esaxerenone in altering the K\textsuperscript{+} levels and renal function are not striking compared with spironolactone and eplerenone.

Safety for blood pressure
For patients with HFrEF, ACE inhibitors or ARBs, β-blockers, and MRBs are recommended [7,8]. However, adding MRBs could lead to hypotension and circulatory failure. In the present study, no patient presented with hypotension, even if in some patients SBP had been already normalized at baseline with other antihypertensive agents. It was suggested that low-dose esaxerenone rarely decreases BP excessively.

Efficacy for HF
Regardless of the cohort, BNP consistently decreased over time. According to a review analyzing 16 phase III chronic HF trials, therapy-related changes in natriuretic peptides appeared
modestly correlated with longer-term therapeutic effects on hospitalization for HF, but not with effects on all-cause mortality [21]. Regarding MRBs, the ARTS-HF study reported that 30–40% of HF patients with diabetes mellitus and/or chronic kidney disease treated with eplerenone or finerenone presented with a >30% reduction of NT-proBNP [22]. Esaxerenone in the present study demonstrated comparable BNP reduction to other MRBs, which suggests that esaxerenone is potentially beneficial for HFrEF.

**Study limitations**

The present study has several limitations. First, this non-randomized observational study without a control group was performed at a single center with a small number of patients for a limited observation period and a Japanese-specific population. Indeed, esaxerenone is currently available only in Japan. Moreover, we were unable to follow-up the patients long-term, which seems to be one reason why the number of AEs was small. In previous studies regarding MRBs, however, K⁺ elevation and eGFR decrease were reported to be most conspicuous within the first month [18,23]. We intended to investigate mainly the safety of the drug; thus, our results have a certain significance regarding safety. A large-scale, multinational, and randomized control study is required to resolve the potential bias. Second, clinic BP data were unavailable in a number of patients. In these patients, home BP records were checked to diagnose hypotension. Based on the medical records, none of the patients discontinued esaxerenone due to hypotension or dizziness. The main purpose of this study was to assess the drug’s safety, which was accomplished with hypotension as the endpoint. Third, the combination of antihypertensive agents other than MRBs was somewhat variable; however, there was no significant difference in the number of antihypertensive agents other than MRBs. Fourth, a minority of patients underwent treatment for acute decompensated HF with intravenous vasodilators and/or diuretics at baseline. BP and BNP levels may be affected by factors other than esaxerenone.

**Conclusions**

The present study suggested that esaxerenone is safe for hypertensive patients with HFrEF, with a low incidence of hyperkalemia and hypotension. Changes in renal function and incidence of WRF were acceptable and similar to those observed in patients treated with spironolactone and eplerenone. Moreover, esaxerenone was found to be beneficial for HF in terms of BNP level reduction.

**Supporting information**

S1 Table. Study data. Patients’ dataset. (XLSX)

**Acknowledgments**

We would like to thank Editage (www.editage.jp) for English language editing.

**Author Contributions**

**Conceptualization:** Togo Iwahana, Yuichi Saito, Sho Okada, Yoshio Kobayashi.

**Data curation:** Yuichi Saito, Ryohei Ono.

**Formal analysis:** Togo Iwahana.

**Funding acquisition:** Togo Iwahana, Yoshio Kobayashi.
**References**

1. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. The Lancet. 2014; 383(9932):1899–911.

2. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012; 25(5):514–23. PMID: 22258336

3. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018; 72(5):e53–e90. https://doi.org/10.1161/HYP.000000000000084 PMID: 30354828

4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–17. https://doi.org/10.1056/NEJM199909023411001 PMID: 10471456

5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309–21. https://doi.org/10.1056/NEJMoa030207 PMID: 12668699

6. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492 PMID: 21073363

7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128 PMID: 27206819

8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136(6):e137–e61. https://doi.org/10.1161/CIR.0000000000000509 PMID: 28455343

9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruijlope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219–29. https://doi.org/10.1056/NEJMoa2025845 PMID: 33264825

10. Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013; 36(3):185–90. https://doi.org/10.1038/hr.2012.182 PMID: 23171954

11. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015; 761:226–34. https://doi.org/10.1016/j.ejphar.2015.06.015 PMID: 26073023

12. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2020; 75(1):51–8. https://doi.org/10.1161/HYPERTENSIONAHA.119.13569 PMID: 31786983

13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982–92. https://doi.org/10.1053/j.ajkd.2008.12.034 PMID: 19339088

14. Naruke T, Maemura K, Oki T, Yazaki M, Fujita T, Ikeda Y, et al. Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. Hypertens Res. 2021. https://doi.org/10.1038/s41440-020-00606-w PMID: 33420475
15. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543–51. https://doi.org/10.1056/NEJMoa040135 PMID: 15295047

16. Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019; 42(10):1572–81. https://doi.org/10.1038/s41440-019-0270-2 PMID: 31239535

17. Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019; 42(12):1932–41. https://doi.org/10.1038/s41440-019-0314-7 PMID: 31554937

18. Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2020. https://doi.org/10.1038/s41440-020-00569-y PMID: 33214722

19. Sato A. Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect? Hypertens Res. 2019; 42(12):1841–7. https://doi.org/10.1038/s41440-019-0320-9 PMID: 31492909

20. Ruiz-Hurtado G, Ruilope LM. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. Eur Heart J Cardiovasc Pharmacother. 2015; 1(2):126–31. https://doi.org/10.1093/ehjcvp/pvu023 PMID: 27533982

21. Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, et al. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC Heart Fail. 2018; 6(7):564–9. https://doi.org/10.1016/j.jchf.2018.02.007 PMID: 29501807

22. Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016; 37(27):2105–14. https://doi.org/10.1093/eurheartj/ehw102 PMID: 27130709

23. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014; 7(1):51–8. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000792 PMID: 24297687